Scientists track experimental cancer pill through the body
NCT ID NCT07444268
Summary
This early study aims to understand how the body absorbs, breaks down, and eliminates a single oral dose of an experimental drug called DSP-5336. It will involve 8 adults with advanced blood cancers (like leukemia or multiple myeloma) that have returned or stopped responding to standard treatments. The main goal is to measure how much of the drug and its byproducts leave the body in urine and stool, and to check for safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of North Carolina
Chapel Hill, North Carolina, 27514, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.